Share

We are delighted to announce that, at the Board meeting on 17th January, George Sutherland was appointed as the first Chairman of TRUEinvivo Ltd. George originally joined our advisory board in 2017 and then became a shareholder and investor director in February 2018. He has been instrumental in helping us find investment partners, notably Nexus Investment Ventures Ltd., whose network members invested around 70% of our first seed round.
George is CEO of the Sutherland Health Group and has a background in medical device companies and major fast moving consumer goods. He has managed business with most of the major UK retailers and Amazon and over 25 years of experience in dealing with the NHS. He has set up, and run private companies, has raised corporate finance pre and post IPO, and founded and run a public company.
Related Posts
This order is for a number of DOSEmapper™ devices and for our DOSEmapper™ Bead Reading Service.
Innovate UK showcases TRUEinvivo® founder for Women in Innovation award, spotlighting Dr. Shakardokht Jafari's success.
Mount Vernon Cancer Centre pioneers first internal invivo dosimetry with TRUEnvivo® DOSEmapper™, revolutionising radiotherapy precision, patient safety, and treatment accuracy.
TRUEinvivo joined SyndicateRoom investment platform in February 2019, leveraging its network to connect with potential investors, alongside Nexus Investment Ventures Ltd,